Prostate cancer often metastasizes to the regional lymph nodes, but metastases to distant supradiaphragmatic lymph nodes are uncommon. Rare case reports describe cervical lymph node metastases as the first clinical manifestation of prostate cancer, but only in the setting of widely disseminated disease. We present the unusual case of an 84-y-old male with a known history of prostate cancer and recurrent disease limited to the left supraclavicular lymph nodes.
Introduction
While lymph nodes are the single most common metastatic site for carcinoma of the prostate, the lymph nodes that are most frequently involved are those of the pelvis and retroperitoneum. 1 Although left supraclavicular nodes have been reported as a site of nonregional, extraskeletal metastases, they are an uncommon presentation of prostate cancer. 2, 3 We present the unusual case of an elderly male with metastatic prostate cancer confined to the left supraclavicular lymph nodes. The majority of cancers metastatic to the cervical lymph nodes are derived from primary malignancies in the mucosal surfaces of the upper aerodigestive tract. Tumors in the head and neck from nonmucosal sources such as skin, salivary glands, and thyroid are the second most common source of cervical node metastases. 4 The higher the level of nodal involvement, the more likely the primary is from the head and neck. 5 Other distant primaries rarely metastasize to the neck, but the most frequently encountered are from the lung, kidney, and breast. 4 To initiate appropriate treatment of metastatic prostate cancer, a histological diagnosis must be established. 6 
Case report
An 84-y-old male was referred to otolaryngology for a left supraclavicular mass. The patient reported increasing swelling on the left side of his neck for approximately 2 months. He denied any other subjective complaints, including difficulty in swallowing or breathing. Physical examination of the patient's neck revealed a nontender left-sided neck mass approximately 4 cm in diameter. Subsequent computerized tomography (CT) scan of the head and neck showed a 4.2 cm, solid left supraclavicular mass with extension from the clavicles to the true vocal cords (Figure 1) . A percutaneous fine needle aspirate (FNA) was performed and interpreted as highly suspicious for malignancy (Figure 2a) . The patient's past medical and surgical history were notable for a diagnosis of prostate cancer 15 years ago, treated with radical retropubic prostatectomy and bilateral pelvic lymph node dissection. The pathology specimen revealed a Gleason score of 2 þ 2, with organconfined prostate cancer. He was first noted to have evidence of recurrent disease approximately 10 months prior, when a prostate-specific antigen (PSA) level of 13.4 ng/ml was detected. Within only 8 months, the patient's PSA level increased to 55.5 ng/ml. Diagnostic work-up included a negative bone scan as well as an unremarkable CT scan of the abdomen and pelvis. In the absence of documented metastatic disease, but a rising PSA, he was initiated on total androgen ablation with leuprolide (Lupron) and bicalutamide (Casodex).
The patient was taken to the operating room for open biopsy of the left neck mass, laryngoscopy with biopsies, bronchoscopy, and esophagoscopy. Biopsy of the left supraclavicular mass showed a moderately differentiated adenocarcinoma consistent with prostatic origin (Figure 2b ). PSA immunohistochemistry was positive. The biopsies performed during direct laryngoscopy were negative for malignancy. Additional diagnostic work-up included a repeat bone scan and CT scan of the chest, abdomen and pelvis, which once again did not demonstrate evidence of other metastases or recurrent disease.
Following tissue diagnosis, the patient's PSA continued to rise, indicating the development of hormonerefractory disease. Additional treatment measures such as secondary hormonal manipulation, systemic chemotherapy, and radiation for local palliation were discussed with the patient who declined further treatment.
Discussion
This case is unique because it presents only the second reported case of prostate cancer metastatic to the neck in An isolated neck metastasis raises issues regarding treatment. While neck dissection has an established role in the treatment of some of the loco-regional malignancies that spread to the cervical lymph nodes, experience with prostate cancer lymph node metastasis to other sites suggests that surgical intervention is of little utility. Cervical lymph node metastasis should be treated as systemic disease and primarily treated with androgen ablation. A potential role for radiation lies in the palliation of local symptoms relating to venous obstruction and/or neural compression.
Finally, this elderly patient experienced a late recurrence of his prostate cancer detected by a rising PSA. This case report illustrates both the need for continued long-term surveillance of patients who have undergone local prostate cancer treatment with curative intent, as well the potential morbidity and mortality of recurrent disease, even in the elderly. The presence of supraclavicular lymphadenopathy emphasizes the importance of a thorough physical examination in every urologic patient, in particular those with a history of malignancy.
Editorial comment
This is the first in a new series for Prostate Cancer and Prostatic Diseases in which we will feature an interesting case regarding the prostate. This case comes from Dr Dahm and colleagues from Duke University and the Duke Prostate Center. Readers are asked to contact Dr Judd Moul, co-editor, if they have an interesting case for consideration. This is a highly unusual case of biochemical recurrence that was associated with isolated supraclavicular lymph node metastases. This patient had a very rapid PSA doubling time (PSA-DT) at less than 3 months, which was recently shown by D'Amico et al to be a direct surrogate of prostate cancer death. 10 Even though no one would argue against hormonal therapy in this setting, it is unclear if it results in longer survival. Moul et al 11 recently reported that men with a biochemical recurrence and a PSA-DT o1 y had delayed clinical metastases (positive bone scans primarily) if they received hormonal therapy before the PSA reached 10.0 ng/ml. However, it is only speculative if the hormonal therapy had been started earlier (say at the PSA of 13.4 ng/ml) of whether the cervical adenopathy would have been delayed or averted.
It will be interesting to see the response duration of hormonal therapy in this setting of soft-tissue-only metastases. Some clinicians feel that soft-tissue disease has a more durable response to hormonal therapy. The nature of this soft-tissue, nonbone metastases pattern at spread is undoubtedly due to the molecular profile of the patient's cancer. Future genomic profiling will hopefully shed more light on this less common pattern of prostate cancer presentation.
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